Clinical Trials · NCT06739044
Efficacy and Safety of Semaglutide Injection vs Ozempic® in Patients With Type 2 Diabetes
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
- Enrollment
- 494
- Start date
- Sep 2023
- Locations
- 1 site, China
- Primary endpoint
- Change in HbA1c from baseline